Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation

Current Opinion in Pharmacology

Volumn 32, Issue , 2017, Pages 49-55

  Hellyer, Shane ^a   Leach, Katie ^a   Gregory, Karen J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOSTERIC MODULATOR; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 7; METABOTROPIC RECEPTOR AGONIST; ORTHOSTERIC AGONIST; UNCLASSIFIED DRUG;

ALLOSTERISM; CENTRAL NERVOUS SYSTEM DISEASE; NEUROBIOLOGY; NEUROMODULATION; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PROCEDURES;

ALLOSTERIC REGULATION; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION;

EID: 84994761123     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2016.10.007     Document Type: Review

References (49)

1. 1 Nickols, H.H., Conn, P.J., Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis 61 (2014), 55–71.
2. 2 O'Brien, D.E., Conn, P.J., Neurobiological insights from mGlu receptor allosteric modulation. Int J Neuropsychopharmacol, 19, 2016, pyv133.
3. 3• Lindsley, C.W., Emmitte, K.A., Hopkins, C.R., Bridges, T.M., Gregory, K.J., Niswender, C.M., Conn, P.J., Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors. Chem Rev 116 (2016), 6707–6741 An excellent review of advanced aspects of mGlu signaling and the development of subtype-specific allosteric ligands.
4. 4 Conn, P.J., Lindsley, C.W., Meiler, J., Niswender, C.M., Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov 13 (2014), 692–708.
5. 5 Kenakin, T., Christopoulos, A., Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12 (2013), 205–216.
6. 6 Sengmany, K., Gregory, K.J., Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias. Br J Pharmacol, 2015.
7. 7 Emery, A.C., DiRaddo, J.O., Miller, E., Hathaway, H.A., Pshenichkin, S., Takoudjou, G.R., Grajkowska, E., Yasuda, R.P., Wolfe, B.B., Wroblewski, J.T., Ligand bias at metabotropic glutamate 1a receptors: molecular determinants that distinguish beta-arrestin-mediated from G protein-mediated signaling. Mol Pharmacol 82 (2012), 291–301.
8. 8 Hathaway, H.A., Pshenichkin, S., Grajkowska, E., Gelb, T., Emery, A.C., Wolfe, B.B., Wroblewski, J.T., Pharmacological characterization of mGlu1 receptors in cerebellar granule cells reveals biased agonism. Neuropharmacology 93 (2015), 199–208.
9. 9 Jalan-Sakrikar, N., Field, J.R., Klar, R., Mattmann, M.E., Gregory, K.J., Zamorano, R., Engers, D.W., Bollinger, S.R., Weaver, C.D., Days, E.L., et al. Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7. ACS Chem Neurosci 5 (2014), 1221–1237.
10. 10•• Sengmany, K., Singh, J., Stewart, G.D., Conn, P.J., Christopoulos, A., Gregory, K.J., Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery. Neuropharmacology, 2016 Excellent manuscript in which authors defined the effects of mGlu5 PAMs on multiple signaling pathways to rigorously analyse biased allosteric agonism and modulation in recombinant cells and primary neuronal cultures.
11. 11•• Rook, J.M., Noetzel, M.J., Pouliot, W.A., Bridges, T.M., Vinson, P.N., Cho, H.P., Zhou, Y., Gogliotti, R.D., Manka, J.T., Gregory, K.J., et al. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Biol Psychiatry 73 (2013), 501–509 Authors demonstrated the antipsychotic properties of a biased mGlu5 PAM and showed for the first time that mGlu5 PAM antipsychotic efficacy does not require potentiation of NMDA currents.
12. 12 Gregory, K.J., Herman, E.J., Ramsey, A.J., Hammond, A.S., Byun, N.E., Stauffer, S.R., Manka, J.T., Jadhav, S., Bridges, T.M., Weaver, C.D., et al. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement. J Pharmacol Exp Ther 347 (2013), 438–457.
13. 13 Rook, J.M., Xiang, Z., Lv, X., Ghoshal, A., Dickerson, J.W., Bridges, T.M., Johnson, K.A., Foster, D.J., Gregory, K.J., Vinson, P.N., et al. Biased mGlu5-Positive allosteric modulators provide in vivo efficacy without potentiating mGlu5 modulation of NMDAR currents. Neuron 86 (2015), 1029–1040.
14. 14 Zhang, Y., Rodriguez, A.L., Conn, P.J., Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J Pharmacol Exp Ther 315 (2005), 1212–1219.
15. 15 Gregory, K.J., Noetzel, M.J., Rook, J.M., Vinson, P.N., Stauffer, S.R., Rodriguez, A.L., Emmitte, K.A., Zhou, Y., Chun, A.C., Felts, A.S., et al. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Mol Pharmacol 82 (2012), 860–875.
16. 16 Niswender, C.M., Johnson, K.A., Miller, N.R., Ayala, J.E., Luo, Q., Williams, R., Saleh, S., Orton, D., Weaver, C.D., Conn, P.J., Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol Pharmacol 77 (2010), 459–468.
17. 17 Noetzel, M.J., Gregory, K.J., Vinson, P.N., Manka, J.T., Stauffer, S.R., Lindsley, C.W., Niswender, C.M., Xiang, Z., Conn, P.J., A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol Pharmacol 83 (2013), 835–847.
18. 2/4 homo- and heterodimers dictate allosteric modulator pharmacology at different synapses.
19. 19 Kammermeier, P.J., Functional and pharmacological characteristics of metabotropic glutamate receptors 2/4 heterodimers. Mol Pharmacol 82 (2012), 438–447.
20. 20 Conde-Ceide, S., Martinez-Viturro, C.M., Alcazar, J., Garcia-Barrantes, P.M., Lavreysen, H., Mackie, C., Vinson, P.N., Rook, J.M., Bridges, T.M., Daniels, J.S., et al. Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. ACS Med Chem Lett 6 (2015), 716–720.
21. 21 Balu, D.T., Li, Y., Takagi, S., Presti, K.T., Ramikie, T.S., Rook, J.M., Jones, C.K., Lindsley, C.W., Conn, P.J., Bolshakov, V.Y., et al. An mGlu5-positive allosteric modulator rescues the neuroplasticity deficits in a genetic model of NMDA receptor hypofunction in schizophrenia. Neuropsychopharmacology 41 (2016), 2052–2061.
22. 22 Garcia-Barrantes, P.M., Cho, H.P., Niswender, C.M., Byers, F.W., Locuson, C.W., Blobaum, A.L., Xiang, Z., Rook, J.M., Conn, P.J., Lindsley, C.W., Development of novel, CNS penetrant positive allosteric modulators for the metabotropic glutamate receptor subtype 1 (mGlu1), based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide scaffold, that potentiate wild type and mutant mGlu1 receptors found in schizophrenics. J Med Chem 58 (2015), 7959–7971.
23. 23 Parmentier-Batteur, S., Hutson, P.H., Menzel, K., Uslaner, J.M., Mattson, B.A., O'Brien, J.A., Magliaro, B.C., Forest, T., Stump, C.A., Tynebor, R.M., et al. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators–development challenges for a promising novel antipsychotic target. Neuropharmacology 82 (2014), 161–173.
24. 24 Yang, F., Snyder, L.B., Balakrishnan, A., Brown, J.M., Sivarao, D.V., Easton, A., Fernandes, A., Gulianello, M., Hanumegowda, U.M., Huang, H., et al. Discovery and preclinical evaluation of BMS-955829, a potent positive allosteric modulator of mGluR5. ACS Med Chem Lett 7 (2016), 289–293.
25. 25 Porter, R.H., Jaeschke, G., Spooren, W., Ballard, T.M., Buttelmann, B., Kolczewski, S., Peters, J.U., Prinssen, E., Wichmann, J., Vieira, E., et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 315 (2005), 711–721.
26. 26 Campbell, U.C., Lalwani, K., Hernandez, L., Kinney, G.G., Conn, P.J., Bristow, L.J., The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl) 175 (2004), 310–318.
27. 27 Rodriguez, A.L., Grier, M.D., Jones, C.K., Herman, E.J., Kane, A.S., Smith, R.L., Williams, R., Zhou, Y., Marlo, J.E., Days, E.L., et al. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol 78 (2010), 1105–1123.
28. 5 NAMs M-5MPEP and Br-5MPEPy have comparable in vivo efficacy to full NAM MTEP in rodent models of cocaine addiction, but did not share the MTEP psychomimetic adverse effect liability.
29. 29 Nickols, H.H., Yuh, J.P., Gregory, K.J., Morrison, R.D., Bates, B.S., Stauffer, S.R., Emmitte, K.A., Bubser, M., Peng, W., Nedelcovych, M.T., et al. VU0477573: partial negative allosteric modulator of the subtype 5 metabotropic glutamate receptor with in vivo efficacy. J Pharmacol Exp Ther 356 (2016), 123–136.
30. 30 Copeland, C.S., Neale, S.A., Salt, T.E., Neuronal activity patterns in the mediodorsal thalamus and related cognitive circuits are modulated by metabotropic glutamate receptors. Neuropharmacology 92 (2015), 16–24.
31. 31 Walker, A.G., Wenthur, C.J., Xiang, Z., Rook, J.M., Emmitte, K.A., Niswender, C.M., Lindsley, C.W., Conn, P.J., Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction. Proc Natl Acad Sci U S A 112 (2015), 1196–1201.
32. 32 Ferguson, B.R., Gao, W.J., Development of thalamocortical connections between the mediodorsal thalamus and the prefrontal cortex and its implication in cognition. Front Hum Neurosci, 8, 2014, 1027.
33. 33 Dhanya, R.P., Sheffler, D.J., Dahl, R., Davis, M., Lee, P.S., Yang, L., Nickols, H.H., Cho, H.P., Smith, L.H., D'Souza, M.S., et al. Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. J Med Chem 57 (2014), 4154–4172.
34. 34 Augier, E., Dulman, R.S., Rauffenbart, C., Augier, G., Cross, A.J., Heilig, M., The mGluR2 positive allosteric modulator, AZD8529 and cue-induced relapse to alcohol seeking in rats. Neuropsychopharmacology, 2016.
35. 35 Justinova, Z., Panlilio, L.V., Secci, M.E., Redhi, G.H., Schindler, C.W., Cross, A.J., Mrzljak, L., Medd, A., Shaham, Y., Goldberg, S.R., The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self-administration and relapse in squirrel monkeys. Biol Psychiatry 78 (2015), 452–462.
36. 36 Li, X., D'Souza, M.S., Nino, A.M., Doherty, J., Cross, A., Markou, A., Attenuation of nicotine-taking and nicotine-seeking behavior by the mGlu2 receptor positive allosteric modulators AZD8418 and AZD8529 in rats. Psychopharmacology (Berl) 233 (2016), 1801–1814.
37. 37 Caprioli, D., Venniro, M., Zeric, T., Li, X., Adhikary, S., Madangopal, R., Marchant, N.J., Lucantonio, F., Schoenbaum, G., Bossert, J.M., et al. Effect of the novel positive allosteric modulator of metabotropic glutamate receptor 2 AZD8529 on incubation of methamphetamine craving after prolonged voluntary abstinence in a rat model. Biol Psychiatry 78 (2015), 463–473.
38. 38 Battaglia, G., Busceti, C.L., Molinaro, G., Biagioni, F., Traficante, A., Nicoletti, F., Bruno, V., Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci 26 (2006), 7222–7229.
39. 39 Ponnazhagan, R., Harms, A.S., Thome, A.D., Jurkuvenaite, A., Gogliotti, R., Niswender, C.M., Conn, P.J., Standaert, D.G., The metabotropic glutamate receptor 4 positive allosteric modulator ADX88178 inhibits inflammatory responses in primary microglia. J Neuroimmune Pharmacol 11 (2016), 231–237.
40. 40 Domin, H., Przykaza, L., Jantas, D., Kozniewska, E., Boguszewski, P.M., Smialowska, M., Neuroprotective potential of the group III mGlu receptor agonist ACPT-I in animal models of ischemic stroke: in vitro and in vivo studies. Neuropharmacology 102 (2016), 276–294.
41. 41 Domin, H., Jantas, D., Smialowska, M., Neuroprotective effects of the allosteric agonist of metabotropic glutamate receptor 7 AMN082 on oxygen-glucose deprivation- and kainate-induced neuronal cell death. Neurochem Int 88 (2015), 110–123.
42. 42 Mitsukawa, K., Yamamoto, R., Ofner, S., Nozulak, J., Pescott, O., Lukic, S., Stoehr, N., Mombereau, C., Kuhn, R., McAllister, K.H., et al. A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. PNAS 102 (2005), 18712–18717.
43. 43•• Klar, R., Walker, A.G., Ghose, D., Grueter, B.A., Engers, D.W., Hopkins, C.R., Lindsley, C.W., Xiang, Z., Conn, P.J., Niswender, C.M., Activation of metabotropic glutamate receptor 7 is required for induction of long-term potentiation at SC-CA1 synapses in the hippocampus. J Neurosci 35 (2015), 7600–7615 An elegant manuscript using a combination of optogenetic and pharmacological techniques to show that mGlu7 receptor activation disinhibits interneurons and enhances LTP at hippocampal synapses.
44. 44 Kalinichev, M., Rouillier, M., Girard, F., Royer-Urios, I., Bournique, B., Finn, T., Charvin, D., Campo, B., Le Poul, E., Mutel, V., et al. ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization. J Pharmacol Exp Therapeut 344 (2013), 624–636.
45. 45 Tassin, V., Girard, B., Chotte, A., Fontanaud, P., Rigault, D., Kalinichev, M., Perroy, J., Acher, F., Fagni, L., Bertaso, F., Phasic and tonic mGlu7 receptor activity modulates the thalamocortical network. Front Neural Circuits, 10, 2016, 31.
46. 46 Palazzo, E., Romano, R., Luongo, L., Boccella, S., De Gregorio, D., Giordano, M.E., Rossi, F., Marabese, I., Scafuro, M.A., de Novellis, V., et al. MMPIP, an mGluR7-selective negative allosteric modulator, alleviates pain and normalizes affective and cognitive behavior in neuropathic mice. Pain 156 (2015), 1060–1073.
47. 47 Moloney, R.D., Golubeva, A.V., O'Connor, R.M., Kalinichev, M., Dinan, T.G., Cryan, J.F., Negative allosteric modulation of the mGlu7 receptor reduces visceral hypersensitivity in a stress-sensitive rat strain. Neurobiol Stress 2 (2015), 28–33.
48. 48 Rovira, X., Trapero, A., Pittolo, S., Zussy, C., Faucherre, A., Jopling, C., Giraldo, J., Pin, J.-P., Gorostiza, P., Goudet, C., et al. OptoGluNAM4.1, a photoswitchable allosteric antagonist for real-time control of mGlu4 receptor activity. Cell Chem Biol, 2016.
49. 5 specific Alloswitch-1, which binds covalently but is only active when exposed to violet light.